Odyssey Therapeutics, Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Odyssey Therapeutics, Inc. (ODTX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$1.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- Odyssey Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $3.35M.
- Odyssey Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$4.77M.
- Odyssey Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-06-30 was -$3.22M.
- Odyssey Therapeutics, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$3.54M.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month |
|---|---|---|
| 2026-06-30 | $3.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.42M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$4.77M 10-Q · filed 2026-06-17 | |
| 2025-06-30 | -$3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.76M 10-Q · filed 2026-08-06 |
| 2025-03-31 | -$3.54M 10-Q · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |